<p>2025 年 10 月 18 日，Sonoma Pharmaceuticals, Inc.宣布立即终止 Bruce Thornton 的执行副总裁兼首席运营官职务。终止原因依据其雇佣协议为正当理由。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>个人</strong></td>
<td>Bruce Thornton</td>
</tr>
<tr>
<td><strong>职位</strong></td>
<td>执行副总裁兼首席运营官</td>
</tr>
<tr>
<td><strong>变更类型</strong></td>
<td>被终止</td>
</tr>
<tr>
<td><strong>生效日期</strong></td>
<td>2025 年 10 月 18 日</td>
</tr>
<tr>
<td><strong>原因</strong></td>
<td>正当理由</td>
</tr>
<tr>
<td><strong>替代信息</strong></td>
<td>未披露</td>
</tr>
<tr>
<td><strong>背景详情</strong></td>
<td>不适用</td>
</tr>
<tr>
<td><strong>董事会/委员会角色变更</strong></td>
<td>未披露</td>
</tr>
</tbody>
</table>
<p>原始 SEC 文件：Sonoma Pharmaceuticals, Inc. [ SNOA ] - 8-K -2025 年 10 月 23 日
<strong>免责声明</strong></p>
<p>这是一个由人工智能生成的摘要，可能包含不准确的信息。请考虑与来源核实重要信息。请注意，此摘要仅基于向 SEC 提交的文件。</p>

Sonoma制药

<p>2025 年 10 月 18 日，Sonoma Pharmaceuticals, Inc. 宣布根据布鲁斯·索恩顿（Bruce Thornton）的雇佣协议，立即因故终止其执行副总裁兼首席运营官职务。替代人选信息尚未披露。该公告于 2025 年 10 月 23 日以原始备案号 SNOA - 8-K 向美国证券交易委员会（SEC）提交</p>

<p>On October 18, 2025, Sonoma Pharmaceuticals, Inc. announced the termination of Bruce Thornton as Executive Vice President and Chief Operating Officer, effective immediately. The termination was for cause as per his employment agreement.</p>
<div class="lb-trans"><p>2025 年 10 月 18 日，Sonoma Pharmaceuticals, Inc.宣布立即终止 Bruce Thornton 的执行副总裁兼首席运营官职务。终止原因依据其雇佣协议为正当理由。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Individual</strong></td>
<td>Bruce Thornton</td>
</tr>
<tr>
<td><strong>Role</strong></td>
<td>Executive Vice President and Chief Operating Officer</td>
</tr>
<tr>
<td><strong>Type of Change</strong></td>
<td>Terminated</td>
</tr>
<tr>
<td><strong>Effective Date</strong></td>
<td>October 18, 2025</td>
</tr>
<tr>
<td><strong>Reason</strong></td>
<td>For cause</td>
</tr>
<tr>
<td><strong>Replacement Info</strong></td>
<td>Not disclosed</td>
</tr>
<tr>
<td><strong>Background Details</strong></td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Board/Committee Role Changes</strong></td>
<td>Not disclosed</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>个人</strong></td>
<td>Bruce Thornton</td>
</tr>
<tr>
<td><strong>职位</strong></td>
<td>执行副总裁兼首席运营官</td>
</tr>
<tr>
<td><strong>变更类型</strong></td>
<td>被终止</td>
</tr>
<tr>
<td><strong>生效日期</strong></td>
<td>2025 年 10 月 18 日</td>
</tr>
<tr>
<td><strong>原因</strong></td>
<td>正当理由</td>
</tr>
<tr>
<td><strong>替代信息</strong></td>
<td>未披露</td>
</tr>
<tr>
<td><strong>背景详情</strong></td>
<td>不适用</td>
</tr>
<tr>
<td><strong>董事会/委员会角色变更</strong></td>
<td>未披露</td>
</tr>
</tbody>
</table>
</div><p>Original SEC Filing: Sonoma Pharmaceuticals, Inc. [ SNOA ] - 8-K - Oct. 23, 2025
<strong>Disclaimer</strong></p>
<div class="lb-trans"><p>原始 SEC 文件：Sonoma Pharmaceuticals, Inc. [ SNOA ] - 8-K -2025 年 10 月 23 日
<strong>免责声明</strong></p>
</div><p>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</p>
<div class="lb-trans"><p>这是一个由人工智能生成的摘要，可能包含不准确的信息。请考虑与来源核实重要信息。请注意，此摘要仅基于向 SEC 提交的文件。</p>
</div>

Sonoma 制药宣布解除执行副总裁的职务